Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical ATNM trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | -2.26% | |
| Outside Day | Range Expansion | -2.26% | |
| Wide Bands | Range Expansion | -2.26% | |
| Up 3 Days in a Row | Strength | -2.26% | |
| Narrow Range Bar | Range Contraction | -1.67% | |
| NR7 | Range Contraction | -1.67% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 2 % | about 20 hours ago | |
| 1.5x Volume Pace | about 21 hours ago | |
| 60 Minute Opening Range Breakdown | about 22 hours ago | |
| Down 1% | about 23 hours ago | |
| Rose Above Previous Day's High | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 06/29/2020
Actinium Pharmaceuticals, Inc. Description
Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Immunology Natural Sciences Immunotherapy Antibodies Monoclonal Antibodies Monoclonal Antibody Chemical Elements Stem Cells Acute Myeloid Leukemia Platform Technology Transplantation Cancer Center Hematopoietic Stem Cell Actinides Bismuth Iodine Cactus Immunotherapy Technology Kettering Cancer Center Memorial Sloan
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.47 |
| 52 Week Low | 4.8 |
| Average Volume | 559,757 |
| 200-Day Moving Average | 9.86 |
| 50-Day Moving Average | 10.11 |
| 20-Day Moving Average | 8.40 |
| 10-Day Moving Average | 8.38 |
| Average True Range | 0.49 |
| ADX | 37.78 |
| +DI | 9.11 |
| -DI | 21.44 |
| Chandelier Exit (Long, 3 ATRs ) | 9.87 |
| Chandelier Exit (Short, 3 ATRs ) | 9.17 |
| Upper Bollinger Band | 9.55 |
| Lower Bollinger Band | 7.26 |
| Percent B (%b) | 0.42 |
| BandWidth | 27.27 |
| MACD Line | -0.52 |
| MACD Signal Line | -0.60 |
| MACD Histogram | 0.0777 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.63 | ||||
| Resistance 3 (R3) | 8.65 | 8.55 | 8.56 | ||
| Resistance 2 (R2) | 8.55 | 8.44 | 8.53 | 8.53 | |
| Resistance 1 (R1) | 8.38 | 8.38 | 8.33 | 8.36 | 8.51 |
| Pivot Point | 8.28 | 8.28 | 8.25 | 8.26 | 8.28 |
| Support 1 (S1) | 8.11 | 8.17 | 8.06 | 8.09 | 7.93 |
| Support 2 (S2) | 8.01 | 8.11 | 7.99 | 7.91 | |
| Support 3 (S3) | 7.84 | 8.01 | 7.88 | ||
| Support 4 (S4) | 7.82 |
